Binod Dhakal

4.9k total citations
163 papers, 1.9k citations indexed

About

Binod Dhakal is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Binod Dhakal has authored 163 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 108 papers in Hematology, 75 papers in Oncology and 74 papers in Molecular Biology. Recurrent topics in Binod Dhakal's work include Multiple Myeloma Research and Treatments (92 papers), Protein Degradation and Inhibitors (36 papers) and CAR-T cell therapy research (31 papers). Binod Dhakal is often cited by papers focused on Multiple Myeloma Research and Treatments (92 papers), Protein Degradation and Inhibitors (36 papers) and CAR-T cell therapy research (31 papers). Binod Dhakal collaborates with scholars based in United States, Germany and Belgium. Binod Dhakal's co-authors include Parameswaran Hari, Saurabh Chhabra, Anita D’Souza, Mehdi Hamadani, Anikó Szabó, Marcelo C. Pasquini, Anand Padmanabhan, Timothy S. Fenske, Meera Mohan and Saad Z. Usmani and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Binod Dhakal

147 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Binod Dhakal United States	24	1.2k	852	792	239	225	163	1.9k
Federico Campigotto United States	17	645 0.6×	342 0.4×	836 1.1×	107 0.4×	297 1.3×	40	2.0k
Shirley D’Sa United Kingdom	25	1.4k 1.2×	628 0.7×	469 0.6×	120 0.5×	400 1.8×	122	2.4k
Michael Koenigsmann Germany	20	405 0.4×	436 0.5×	227 0.3×	176 0.7×	296 1.3×	63	1.5k
Malin Hultcrantz United States	22	1.5k 1.3×	516 0.6×	893 1.1×	69 0.3×	227 1.0×	113	2.2k
Manfred Mitterer Italy	21	293 0.3×	526 0.6×	284 0.4×	82 0.3×	279 1.2×	58	1.3k
M. Fevzi Özkaynak United States	19	316 0.3×	783 0.9×	854 1.1×	219 0.9×	469 2.1×	66	2.4k
Silvia Park South Korea	21	650 0.6×	581 0.7×	299 0.4×	122 0.5×	218 1.0×	163	1.5k
Henry C. Fung United States	25	839 0.7×	790 0.9×	309 0.4×	125 0.5×	302 1.3×	99	2.1k
Hans Hägglund Sweden	24	1.1k 0.9×	406 0.5×	173 0.2×	226 0.9×	482 2.1×	57	1.9k
Maria Elisa Mancuso Italy	34	4.0k 3.5×	243 0.3×	694 0.9×	287 1.2×	77 0.3×	178	4.6k

Countries citing papers authored by Binod Dhakal

Since Specialization

Citations

This map shows the geographic impact of Binod Dhakal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Binod Dhakal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Binod Dhakal more than expected).

Fields of papers citing papers by Binod Dhakal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Binod Dhakal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Binod Dhakal. The network helps show where Binod Dhakal may publish in the future.

Co-authorship network of co-authors of Binod Dhakal

This figure shows the co-authorship network connecting the top 25 collaborators of Binod Dhakal. A scholar is included among the top collaborators of Binod Dhakal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Binod Dhakal. Binod Dhakal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chari, Ajai, Susan Bal, Sikander Ailawadhi, et al.. (2025). Expert Perspectives on Current Challenges and Emerging Approaches for Multiple Myeloma: Narrative Review of an Inaugural Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 25(9). 635–645.

Dhakal, Binod, Nina Kim, William S. John, et al.. (2024). Real-World Patient Characteristics and Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Receiving Teclistamab across Community Oncology Practices in the US. Blood. 144(Supplement 1). 7843–7843. 1 indexed citations

Dhakal, Binod, et al.. (2024). Novel Approaches of Cellular Therapy in Multiple Myeloma: Focus on Chimeric Antigen Receptor T-Cells. Acta Haematologica. 148(3). 330–345. 3 indexed citations

Costa, Luciano J., Eva Medvedova, Binod Dhakal, et al.. (2024). Implications of MRD Progression in Newly Diagnosed Multiple Myeloma (NDMM) Treated with Quadruplet Therapy and Autologous Stem Cell Transplantation. Blood. 144(Supplement 1). 363–363. 1 indexed citations

Nyati, Kishan Kumar, Tarang Sharma, Binod Dhakal, et al.. (2024). CD47-CD138 Bispecific Antibody Exhibits Selective Targeting of Multiple Myeloma. Blood. 144(Supplement 1). 4812–4812. 1 indexed citations

Furqan, Fateeha, Binod Dhakal, Timothy S. Fenske, et al.. (2024). Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention. Blood Advances. 8(16). 4320–4329. 5 indexed citations

Dhakal, Binod. (2024). Point-CounterpointChimeric Antigen Receptor T-cell Therapy for First Relapse in Multiple Myeloma: A Promising Strategy. The Hematologist. 21(3).

Li, Jianrong, Shahram Arsang‐Jang, Yan Cheng, et al.. (2024). Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing. Blood Cancer Journal. 14(1). 38–38. 4 indexed citations

Abid, Muhammad Bilal, Anikó Szabó, Walter Longo, et al.. (2023). Efficacy of Multiple SARS-CoV-2 Vaccine Doses in Patients with B Cell Hematologic Malignancies Receiving Chimeric Antigen Receptor T Cell Therapy: A Contemporary Cohort Analysis. Transplantation and Cellular Therapy. 30(3). 285–297. 9 indexed citations

10.

Kanate, Abraham S., Navneet S. Majhail, Zachariah DeFilipp, et al.. (2023). Updated Indications for Immune Effector Cell Therapy: 2023 Guidelines from the American Society for Transplantation and Cellular Therapy. Transplantation and Cellular Therapy. 29(10). 594–597. 25 indexed citations

11.

Shi, Yijiang, Fumou Sun, Yan Cheng, et al.. (2022). Critical Role for Cap-Independent c-MYC Translation in Progression of Multiple Myeloma. Molecular Cancer Therapeutics. 21(4). 502–510. 4 indexed citations

12.

Dong, Jing, Emma Garacci, Anita D’Souza, et al.. (2022). Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study. Blood Cancer Journal. 12(2). 34–34. 25 indexed citations

13.

Chhabra, Saurabh, Rebecca Silbermann, Bhagirathbhai Dholaria, et al.. (2021). Outcomes of Hematopoietic Progenitor Cells Mobilization and Collection Following Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone Induction in Newly Diagnosed Multiple Myeloma. Transplantation and Cellular Therapy. 27(3). S70–S70.

14.

Mohan, Meera, Binod Dhakal, Sabarinath Venniyil Radhakrishnan, et al.. (2021). Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma. Blood Advances. 6(8). 2466–2470. 34 indexed citations

15.

Dhakal, Binod, Parameswaran Hari, Saad Z. Usmani, & Mehdi Hamadani. (2020). Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges. Bone Marrow Transplantation. 56(1). 9–19. 23 indexed citations

16.

Dhakal, Binod, Smith Giri, Anikó Szabó, et al.. (2020). Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta‐analysis of phase 3 randomized controlled trials. Cancer. 126(12). 2791–2801. 4 indexed citations

17.

Knight, Jennifer M., J. Douglas Rizzo, Parameswaran Hari, et al.. (2020). Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial. Blood Advances. 4(3). 467–476. 39 indexed citations

18.

Murthy, Guru Subramanian Guru, Parameswaran Hari, Anikó Szabó, et al.. (2018). Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. Biology of Blood and Marrow Transplantation. 25(4). 827–833. 24 indexed citations

19.

Dhakal, Binod, Ariel Ann Nelson, Guru Subramanian Guru Murthy, et al.. (2016). Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age. Clinical Lymphoma Myeloma & Leukemia. 17(3). 165–172. 13 indexed citations

20.

Dhakal, Binod, Christopher Strouse, Anita D’Souza, et al.. (2014). Plerixafor and Abbreviated-Course Granulocyte Colony–Stimulating Factor for Mobilizing Hematopoietic Progenitor Cells in Light Chain Amyloidosis. Biology of Blood and Marrow Transplantation. 20(12). 1926–1931. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact